Validation and Implementation of a Somatic-Only Tumor Exome for Routine Clinical Application

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Next-generation sequencing (NGS) is crucial for cancer genomic testing but faces institutional challenges due to varied needs and resources.
• Diverse gene panels lead to unequal patient care, highlighting the need for standardization without restrictive kits or costly revalidations.

Purpose of the Study:

• To validate and clinically implement the DH-CancerSeq assay, a novel whole-exome sequencing approach.
• To establish a standardized, cost-effective genomic testing method for diverse institutional settings.

Main Methods:

• Development and validation of the DH-CancerSeq assay, a tumor-only whole-exome sequencing assay.
• Integration of informatics for streamlined data analysis.
• Comparative analysis of DH-CancerSeq against a validated targeted gene panel.

Main Results:

• The DH-CancerSeq assay demonstrated comparable input requirements, sensitivity, and specificity to existing targeted gene panels.
• Similar turnaround times were maintained, ensuring timely patient care.
• Successful clinical implementation across diverse institutional settings was achieved.

Conclusions:

• The DH-CancerSeq assay provides a standardized and validated whole-exome sequencing solution for tumor genomic testing.
• This approach addresses the challenges of resource variability and promotes equitable patient care globally.
• DH-CancerSeq offers a cost-effective alternative to traditional targeted panels, enhancing clinical utility.